Heat Biologics Quote - HTBX

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

2.83

Bid

2.81

Offer

2.89

Volume

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Market Cap

73.812M

Previous Close

2.83

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

Shares Outstanding

26,082,000

Dividend Yield

PE Ratio

-0.13

Earnings Per Share (EPS)

-1.73

Revenue

Net Profit

-45.22M

Heat Biologics Inc is an immuno-oncology company. It is engaged in developing therapies that activate a patient's immune system against cancer utilizing an engineered form of gp96. The group's T cell-stimulating therapeutic vaccine platform technologies, Immune Pan-Antigen Cytotoxic Therapy and Comb... Heat Biologics Inc is an immuno-oncology company. It is engaged in developing therapies that activate a patient's immune system against cancer utilizing an engineered form of gp96. The group's T cell-stimulating therapeutic vaccine platform technologies, Immune Pan-Antigen Cytotoxic Therapy and Combination Pan-Antigen Cytotoxic Therapy form the basis of its product candidates. Through ImPACT, it developed product candidates consisting of live, genetically modified, irradiated human cancer cells that secrete tumour-associated antigens together with an immune response stimulator called gp96. Through ComPACT, the firm engineered product candidates that incorporate ligand fusion proteins targeting co-stimulatory receptors into the gp96-Ig expression vector. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

ir.scorpiusbiologics.com/

Headquarters

Wilmington, Delaware, USA

Founded

Heat Biologics Announces Planned Transfer to the NYSE American

DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to...

Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, Its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services

Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023 Reaffirms ANTHIM as an important medical countermeasure in the U.S...

Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110

DURHAM, N.C., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to...

Heat Biologics Announces Planned Acquisition of Elusys Therapeutics

DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to...

Heat Biologics Unveils RapidVax®, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats

Designed for rapid “plug and play” programming and stockpiling against emerging infectious agents and viral mutations Emergence of Omicron and other COVID-19 variants underscores the need for a...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

HTBX - Frequently Asked Questions (FAQ)

What is the current Heat Biologics share price?

The current share price of Heat Biologics is US$ 2.83

How many Heat Biologics shares are in issue?

Heat Biologics has 26,082,000 shares in issue

What is the market cap of Heat Biologics?

The market capitalisation of Heat Biologics is USD 73.81M

What is the 1 year trading range for Heat Biologics share price?

Heat Biologics has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the PE ratio of Heat Biologics?

The price to earnings ratio of Heat Biologics is -0.13

What is the cash to sales ratio of Heat Biologics?

The cash to sales ratio of Heat Biologics is 0.86

What is the reporting currency for Heat Biologics?

Heat Biologics reports financial results in USD

What is the latest annual turnover for Heat Biologics?

The latest annual turnover of Heat Biologics is USD 7M

What is the latest annual profit for Heat Biologics?

The latest annual profit of Heat Biologics is USD -45.22M

What is the registered address of Heat Biologics?

The registered address for Heat Biologics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808

What is the Heat Biologics website address?

The website address for Heat Biologics is ir.scorpiusbiologics.com/

Which industry sector does Heat Biologics operate in?

Heat Biologics operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CAPTCaptiVision Inc	US$ 1.024 (133.26%)	246M
QNTMQuantum Biopharma Ltd	US$ 6.70 (110.69%)	78.56M
LTRYLottery com Inc	US$ 0.58 (85.90%)	129.21M
CPIXCumberland Pharmaceutical Inc	US$ 3.7801 (77.47%)	18.49M
INKTMiNK Therapeutics Inc	US$ 12.08 (53.69%)	350.86k
OMGAOmega Therapeutics Inc	US$ 0.1473 (-69.25%)	11.43M
VIRXViracta Therapeutics Inc	US$ 0.0352 (-54.76%)	5.54M
CYNCYNGN Inc	US$ 0.0708 (-39.44%)	134.64M
UPCUniverse Pharmaceuticals Inc	US$ 0.2663 (-36.20%)	1.8M
CSAICloudastructure Inc	US$ 12.98 (-31.68%)	53.38k
NVDANVIDIA Corporation	US$ 118.65 (1.71%)	256.77M
CAPTCaptiVision Inc	US$ 1.024 (133.26%)	246M
PLTRPalantir Technologies Inc	US$ 103.83 (23.99%)	230.5M
RGTIRigetti Computing Inc	US$ 13.71 (1.78%)	159.64M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.1518 (-22.11%)	142.77M